Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for SRP-1001 in Facioscapulohumeral muscular dystrophy (FSHD). The expected timing is based on the latest available company guidance and may change.
8/6/25- Preliminary data in H2 2025. 11/03/25:- SAD enrollment complete, MAD cohort 6 ongoing; Ph1/2 SAD and MAD readouts for FSHD expected in early 2026. 02/25/26:- FSHD siRNA program highlighted among five clinical-stage RNA interference therapies with multiple readouts ahead. 03/25/26:- Early Ph1/2 ascending-dose results to be presented in webcast on March 25, 2026. 05/06/26:- First Ph1/2 SRP-1001 data in FSHD1 show dose-dependent exposure, early biomarker effects, and favorable tolerability. 08/05/26:- FSHD Phase 1/2 MAD cohort readouts remain expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.